51 related articles for article (PubMed ID: 15799955)
1. Comparison of 3 AT1 receptor binding assays: filtration assay, ScreenReady Target, and WGA Flashplate.
Van Der Hee RM; Deurholt T; Gerhardt CC; De Groene EM
J Biomol Screen; 2005 Mar; 10(2):118-26. PubMed ID: 15799955
[TBL] [Abstract][Full Text] [Related]
2. High-throughput receptor-binding methods for somatostatin receptor 2.
Birzin ET; Rohrer SP
Anal Biochem; 2002 Aug; 307(1):159-66. PubMed ID: 12137793
[TBL] [Abstract][Full Text] [Related]
3. Brain AT1 angiotensin receptor subtype binding: importance of peptidase inhibition for identification of angiotensin II as its endogenous ligand.
Karamyan VT; Gadepalli R; Rimoldi JM; Speth RC
J Pharmacol Exp Ther; 2009 Oct; 331(1):170-7. PubMed ID: 19587313
[TBL] [Abstract][Full Text] [Related]
4. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay.
Meng T; Su HR; Binkert C; Fischli W; Zhou L; Shen JK; Wang MW
Acta Pharmacol Sin; 2008 Apr; 29(4):517-27. PubMed ID: 18358099
[TBL] [Abstract][Full Text] [Related]
5. Distinct binding mode of 125I-AngII to AT1 receptor without the Cys18-Cys274 disulfide bridge.
Martin RP; Rodrigues ES; Pacheco NA; Corrêa SA; Oliveira SM; Oliveira L; Nakaie CR; Shimuta SI
Regul Pept; 2009 Nov; 158(1-3):14-8. PubMed ID: 19651161
[TBL] [Abstract][Full Text] [Related]
6. Properties of [3H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor.
Nouet S; Dodey P; Renaut P; Marie J; Pruneau D; Larguier R; Lombard C; Bonnafous JC
Mol Pharmacol; 1994 Oct; 46(4):693-701. PubMed ID: 7969048
[TBL] [Abstract][Full Text] [Related]
7. Development of a scintillation proximity assay binding method for the human 5-hydroxytryptamine 6 receptor using intact cells.
Carrick T; Kowal D; Nawoschik S; Zhang G; Chan K; Dunlop J
Anal Biochem; 2008 Oct; 381(1):27-32. PubMed ID: 18601889
[TBL] [Abstract][Full Text] [Related]
8. Determination of ligand binding affinities for endogenous seven-transmembrane receptors using fluorometric microvolume assay technology.
Mellentin-Michelotti J; Evangelista LT; Swartzman EE; Miraglia SJ; Werner WE; Yuan PM
Anal Biochem; 1999 Aug; 272(2):182-90. PubMed ID: 10415087
[TBL] [Abstract][Full Text] [Related]
9. WGA-coated yttrium oxide beads enable an imaging-based adenosine 2a receptor binding scintillation proximity assay suitable for high throughput screening.
Bryant R; McGuinness D; Turek-Etienne T; Guyer D; Yu L; Howells L; Caravano J; Zhai Y; Lachowicz J
Assay Drug Dev Technol; 2004 Jun; 2(3):290-9. PubMed ID: 15285910
[TBL] [Abstract][Full Text] [Related]
10. Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor.
Hansen JL; Haunsø S; Brann MR; Sheikh SP; Weiner DM
Mol Pharmacol; 2004 Mar; 65(3):770-7. PubMed ID: 14978256
[TBL] [Abstract][Full Text] [Related]
11. Mutagenesis of the AT1 receptor reveals different binding modes of angiotensin II and [Sar1]-angiotensin II.
Santos EL; Pesquero JB; Oliveira L; Paiva AC; Costa-Neto CM
Regul Pept; 2004 Jul; 119(3):183-8. PubMed ID: 15120479
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Clin Sci (Lond); 2000 Oct; 99(4):331-41. PubMed ID: 10995600
[TBL] [Abstract][Full Text] [Related]
13. Development of a homogeneous binding assay for histamine receptors.
Crane K; Shih DT
Anal Biochem; 2004 Dec; 335(1):42-9. PubMed ID: 15519569
[TBL] [Abstract][Full Text] [Related]
14. Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes.
Weiland F; Verspohl EJ
Horm Metab Res; 2008 Nov; 40(11):760-6. PubMed ID: 18711690
[TBL] [Abstract][Full Text] [Related]
15. Use of scintillation proximity assay to measure radioligand binding to immobilized receptors without separation of bound from free ligand.
Berry J; Price-Jones M; Killian B
Methods Mol Biol; 2012; 897():79-94. PubMed ID: 22674161
[TBL] [Abstract][Full Text] [Related]
16. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
Albizu L; Teppaz G; Seyer R; Bazin H; Ansanay H; Manning M; Mouillac B; Durroux T
J Med Chem; 2007 Oct; 50(20):4976-85. PubMed ID: 17850055
[TBL] [Abstract][Full Text] [Related]
17. Miniaturization of fluorescence polarization receptor-binding assays using CyDye-labeled ligands.
Harris A; Cox S; Burns D; Norey C
J Biomol Screen; 2003 Aug; 8(4):410-20. PubMed ID: 14567793
[TBL] [Abstract][Full Text] [Related]
18. Radioligand binding assays: application of [(125)I]angiotensin II receptor binding.
Leifert WR; Bucco O; Abeywardena MY; Patten GS
Methods Mol Biol; 2009; 552():131-41. PubMed ID: 19513646
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity.
Georgsson J; Sköld C; Plouffe B; Lindeberg G; Botros M; Larhed M; Nyberg F; Gallo-Payet N; Gogoll A; Karlén A; Hallberg A
J Med Chem; 2005 Oct; 48(21):6620-31. PubMed ID: 16220978
[TBL] [Abstract][Full Text] [Related]
20. A generic particle-based nonradioactive homogeneous multiplex method for high-throughput screening using microvolume fluorimetry.
Martens C; Bakker A; Rodriguez A; Mortensen RB; Barrett RW
Anal Biochem; 1999 Aug; 273(1):20-31. PubMed ID: 10452795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
